The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin

Jaewon Oh, Jong Youn Kim, Sungha Park, Jong Chan Youn, Nak Hoon Son, Dong Jik Shin, Sang Hak Lee, Seok Min Kang, Sun Ha Jee, Yangsoo Jang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Insulin-like growth factor-1 (IGF-1) is associated with obesity and aging, and was recently linked to metabolic syndrome (MetS) and insulin resistance. However, little is known about the relationship between IGF-1 and adiponectin (adiponectin), another marker of MetS. Methods: We measured the plasma IGF-1 and adiponectin levels of 3099 subjects (1869 males, 55.9. ± 10.8. y). We applied the Korean-modified International Diabetes Foundation (k-IDF) criteria for determination of, and risk assessment for, MetS. Results: K-IDF criteria-based MetS occurred in 37.0% (n = 1146) of patients. IGF-1 (91.5 vs. 97.3. ng/ml, p. < 0.001) and adiponectin (3.95 vs. 4.23. μg/ml, p. < 0.001) were significantly lower in MetS patients than without MetS. Lower IGF-1 was associated with increasing numbers of MetS abnormalities, independent of adiponectin (p for trend. < 0.001, F = 12.615, p. < 0.001 in ANCOVA). MetS prevalence in individuals with both high IGF-1 and adiponectin levels (6.7%, n = 206) was significantly lower than in other groups. Both high IGF-1 and adiponectin group was associated with reduced MetS risk after adjusting for other confounding factors (OR 0.694, 95% CI 0.493-0.977, p = 0.036). Conclusions: IGF-1 was associated with MetS independent of adiponectin in our study. The independent relationship between IGF-1 and MetS provides insight into the pathophysiologic mechanisms of MetS.

Original languageEnglish
Pages (from-to)506-510
Number of pages5
JournalClinica Chimica Acta
Volume413
Issue number3-4
DOIs
Publication statusPublished - 2012 Feb 18

Fingerprint

Adiponectin
Somatomedins
Medical problems
Risk assessment
Aging of materials
Insulin
Plasmas
Insulin Resistance
Obesity

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Oh, Jaewon ; Kim, Jong Youn ; Park, Sungha ; Youn, Jong Chan ; Son, Nak Hoon ; Shin, Dong Jik ; Lee, Sang Hak ; Kang, Seok Min ; Jee, Sun Ha ; Jang, Yangsoo. / The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin. In: Clinica Chimica Acta. 2012 ; Vol. 413, No. 3-4. pp. 506-510.
@article{eab6c7902ec04e12b832538ca89bfaee,
title = "The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin",
abstract = "Background: Insulin-like growth factor-1 (IGF-1) is associated with obesity and aging, and was recently linked to metabolic syndrome (MetS) and insulin resistance. However, little is known about the relationship between IGF-1 and adiponectin (adiponectin), another marker of MetS. Methods: We measured the plasma IGF-1 and adiponectin levels of 3099 subjects (1869 males, 55.9. ± 10.8. y). We applied the Korean-modified International Diabetes Foundation (k-IDF) criteria for determination of, and risk assessment for, MetS. Results: K-IDF criteria-based MetS occurred in 37.0{\%} (n = 1146) of patients. IGF-1 (91.5 vs. 97.3. ng/ml, p. < 0.001) and adiponectin (3.95 vs. 4.23. μg/ml, p. < 0.001) were significantly lower in MetS patients than without MetS. Lower IGF-1 was associated with increasing numbers of MetS abnormalities, independent of adiponectin (p for trend. < 0.001, F = 12.615, p. < 0.001 in ANCOVA). MetS prevalence in individuals with both high IGF-1 and adiponectin levels (6.7{\%}, n = 206) was significantly lower than in other groups. Both high IGF-1 and adiponectin group was associated with reduced MetS risk after adjusting for other confounding factors (OR 0.694, 95{\%} CI 0.493-0.977, p = 0.036). Conclusions: IGF-1 was associated with MetS independent of adiponectin in our study. The independent relationship between IGF-1 and MetS provides insight into the pathophysiologic mechanisms of MetS.",
author = "Jaewon Oh and Kim, {Jong Youn} and Sungha Park and Youn, {Jong Chan} and Son, {Nak Hoon} and Shin, {Dong Jik} and Lee, {Sang Hak} and Kang, {Seok Min} and Jee, {Sun Ha} and Yangsoo Jang",
year = "2012",
month = "2",
day = "18",
doi = "10.1016/j.cca.2011.11.015",
language = "English",
volume = "413",
pages = "506--510",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "3-4",

}

The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin. / Oh, Jaewon; Kim, Jong Youn; Park, Sungha; Youn, Jong Chan; Son, Nak Hoon; Shin, Dong Jik; Lee, Sang Hak; Kang, Seok Min; Jee, Sun Ha; Jang, Yangsoo.

In: Clinica Chimica Acta, Vol. 413, No. 3-4, 18.02.2012, p. 506-510.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin

AU - Oh, Jaewon

AU - Kim, Jong Youn

AU - Park, Sungha

AU - Youn, Jong Chan

AU - Son, Nak Hoon

AU - Shin, Dong Jik

AU - Lee, Sang Hak

AU - Kang, Seok Min

AU - Jee, Sun Ha

AU - Jang, Yangsoo

PY - 2012/2/18

Y1 - 2012/2/18

N2 - Background: Insulin-like growth factor-1 (IGF-1) is associated with obesity and aging, and was recently linked to metabolic syndrome (MetS) and insulin resistance. However, little is known about the relationship between IGF-1 and adiponectin (adiponectin), another marker of MetS. Methods: We measured the plasma IGF-1 and adiponectin levels of 3099 subjects (1869 males, 55.9. ± 10.8. y). We applied the Korean-modified International Diabetes Foundation (k-IDF) criteria for determination of, and risk assessment for, MetS. Results: K-IDF criteria-based MetS occurred in 37.0% (n = 1146) of patients. IGF-1 (91.5 vs. 97.3. ng/ml, p. < 0.001) and adiponectin (3.95 vs. 4.23. μg/ml, p. < 0.001) were significantly lower in MetS patients than without MetS. Lower IGF-1 was associated with increasing numbers of MetS abnormalities, independent of adiponectin (p for trend. < 0.001, F = 12.615, p. < 0.001 in ANCOVA). MetS prevalence in individuals with both high IGF-1 and adiponectin levels (6.7%, n = 206) was significantly lower than in other groups. Both high IGF-1 and adiponectin group was associated with reduced MetS risk after adjusting for other confounding factors (OR 0.694, 95% CI 0.493-0.977, p = 0.036). Conclusions: IGF-1 was associated with MetS independent of adiponectin in our study. The independent relationship between IGF-1 and MetS provides insight into the pathophysiologic mechanisms of MetS.

AB - Background: Insulin-like growth factor-1 (IGF-1) is associated with obesity and aging, and was recently linked to metabolic syndrome (MetS) and insulin resistance. However, little is known about the relationship between IGF-1 and adiponectin (adiponectin), another marker of MetS. Methods: We measured the plasma IGF-1 and adiponectin levels of 3099 subjects (1869 males, 55.9. ± 10.8. y). We applied the Korean-modified International Diabetes Foundation (k-IDF) criteria for determination of, and risk assessment for, MetS. Results: K-IDF criteria-based MetS occurred in 37.0% (n = 1146) of patients. IGF-1 (91.5 vs. 97.3. ng/ml, p. < 0.001) and adiponectin (3.95 vs. 4.23. μg/ml, p. < 0.001) were significantly lower in MetS patients than without MetS. Lower IGF-1 was associated with increasing numbers of MetS abnormalities, independent of adiponectin (p for trend. < 0.001, F = 12.615, p. < 0.001 in ANCOVA). MetS prevalence in individuals with both high IGF-1 and adiponectin levels (6.7%, n = 206) was significantly lower than in other groups. Both high IGF-1 and adiponectin group was associated with reduced MetS risk after adjusting for other confounding factors (OR 0.694, 95% CI 0.493-0.977, p = 0.036). Conclusions: IGF-1 was associated with MetS independent of adiponectin in our study. The independent relationship between IGF-1 and MetS provides insight into the pathophysiologic mechanisms of MetS.

UR - http://www.scopus.com/inward/record.url?scp=84355163128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355163128&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.11.015

DO - 10.1016/j.cca.2011.11.015

M3 - Article

C2 - 22133783

AN - SCOPUS:84355163128

VL - 413

SP - 506

EP - 510

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 3-4

ER -